the determination of a tumour associated antigen (CA15.3) (Tobias et al., 1985) defined through two breast specific monoclonal antibodies (DF3, 115D8) (Hilkens et al., 1984; Kufe et al., 1984) . Several investigators were prompted to evaluate the clinical usefulness of the new tumour marker CA15.3 in patients with breast cancer because no breast specific tumour marker was available as yet. Results from clinical studies published to date show that CA15.3 is effective in the follow-up of patients treated for primary breast cancer. Indeed, any significant increase of the marker may allow an early detection of relapse (Maigre et al., 1988) and is probably related to a poorer prognosis al., 1988; Ruibal et al., 1987) . Moreover, the variations of CA15.3 levels are in relation to the effectiveness of the therapy of disseminated breast cancer (Maigre et al., 1988) . Several investigations reported that CA15.3 is more effective in the monitoring of patients with breast cancer than the traditional 'broad spectrum' tumour markers, with CAl 5.3 being certainly more specific and probably more sensitive than CEA (Colomer et al., 1989; Delarue et al., 1988; Hoffman et al., 1987; Jager et al., 1986; Ruibal et al., 1987; .
In spite of the bulk of data regarding advanced breast cancer, the relationships between CA15.3 preoperatory levels and other clinical and biological parameters in patients with primary breast cancer have not been thoroughly evaluated and results are still conflicting. Indeed, it has been demonstrated that CA15.3 has no diagnostic role in discriminating between primary breast cancer and benign breast diseases, due to the low positivity rate of the marker in patients with early breast carcinoma (Gion et al., 1986b (Cox, 1972 ) and the product-limit method (Mantel, 1966 Figure 1 . The differences between stage I and II were not significant (P = 0.367). The antigen concentration was significantly higher in stage III than in stage I (P = 0.045) and II (P = 0.006). Positivity rates were also significantly higher in stage III than in stage I and II using both the cut-off points (Table III) .
Tumour size CA15.3 serum levels were not statistically related to clinical T. However, the assessment of clinical T is inaccurate and imprecise, so that pT is now considered the only reliable parameter of tumour size. A statistically significant direct correlation was found between CAl 5.3 and the tumour diameter (cases 494, r = 0.106, P = 0.018). Significantly higher levels were found in pT3 than in pTI (P = 0.005) and pT2 (P = 0.016) (Figure 2 ). Positivity rates eWithin 2 years from their last menstrual period. Figure 3 . CA15.3 levels were significantly higher in cases with more than three positive lymph nodes than in both cases with 1-3 positive (P = 0.0002) and no positive lymph nodes (P < 0.0001). Positivity rates were also significantly higher in cases with more than three positive fymph nodes than in both cases with no positive and one to three positive lymph nodes (Table III) Figure 4 shows the plot of the significativity of differences of both relapse free survival and the overall survival between CA15.3 positive and negative cases vs the different cut-off points. The value of 30 u ml-' was the best cut-off for both overall survival and relapse free survival. 
Discussion
The study of tumour markers in breast cancer has been merely focused on patients follow-up because the early detection of relapse is a critical target in oncology. However, in breast cancer this is true only from a theoretical point of view, since the early detection of the relapse, given the available therapeutic tools, probably does not improve either the patient survival or the quality of the residual life (Ciatto et al., 1985; Kindler & Sateinhoff, 1989; Urban, 1986) . The study of serum tumour marker levels in patients bearing the primary tumour probably does not affect the clinical course of the disease more efficiently than the study of tumour markers in the follow-up. Nevertheless, it allows an accurate basic study of the relationships between the marker and both clinical and pathological characteristics of the neoplasia.
In previously published papers the relationships between preoperatory CA15.3 levels and clinical stage, tumour size, axillary status, and receptors status were studied anecdotically and results are still conflicting. Preliminary results of our group showed a significant relationship between CA15.3 and both tumour size and the number of positive lymph nodes in 149 cases (Gion et al., 1986b) (Maigre et al., 1988; Schmidt-Rhode et al., 1987 . On the contrary, Jager et al. showed a higher positivity rate in N + than in Ncases, but they did not refer to any evaluation of tumour size (Jager et al., 1986) .
In the present investigation we studied the relationships between CAl 5.3 preoperatory levels and several parameters in a large patient series. CA15.3 levels were higher in patients with locally more advanced disease (stage III, pT3, number of positive lymph nodes >3). The capability of CA15.3 serum levels to detect small variations of tumour bulk was improved when stratifying cases according to pT or axillary status. The subdivision of patients according to tumour size demonstrated that CAl 5.3 levels in cases with smaller tumours were also significantly related to minor differences in axillary status. (nil vs one to three positive lymph nodes). On the other hand, stratifying cases on the basis of axillary status, we demonstrated that CA15.3 was capable of distinguishing as significantly different pTl from pT2 cases in N-patients. Therefore, the relationships between CAl 5.3 and both pT and axillary status are probably independent. These findings suggest that CAl 5.3 serum levels are certainly related to the tumour burden and probably to the tendency of the malignancy to metastatise (number of positive lymph nodes in small tumours). Surprisingly, no relationships were found between CA15.3 and prognosis. However, the latter evaluation was possible only in a limited number of cases.
The prognostic role of preoperatory serum CAl 5.3 determination is therefore under investigation in a wider patient series.
The higher CA15.3 levels found in medullary carcinomas, although this histologic type represents a limited percentage of all breast cancers, suggests that the marker may be usefully used in the monitoring of the disease.
The lack of relationship between CA15.3 serum levels and the receptor status indicates that the two parameters are independent of each other. This is in agreement with both previously published studies of our group (Gion et al., 1986a; Gion et al., 1987) , in which no relationships were found between receptor status and cytosol CA15.3 levels, and results of a clinical study performed by Krebs et al. (Krebs et al., 1988) .
From the above findings we can draw the following conclusions:
(1) CA15.3 is a parameter of both tumour bulk (tumour size, lymph nodal status) and the tendency towards local invasiveness (axillary metastasis in pTI tumours); (2) significant tumour marker variations related to clinical or pathological parameters occur within the normal range. Therefore, quantitative information provided by a kinetic evaluation of the time related variations of the marker levels should be preferred to the dichotomic positive/ negative assessment (qualitative information) currently obtained using conventional cut-off point.
